Last updated: 11/07/2018 19:19:25
A randomized, double-blind, parallel group, comparison of inhaled salmeterol xinafoate (42mcg BID) with oral zafirlukast (20mg BID) in subjects with mild to moderate asthma.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A randomized, double-blind, parallel group, comparison of inhaled salmeterol xinafoate (42mcg BID) with oral zafirlukast (20mg BID) in subjects with mild to moderate asthma.
Trial description: A randomized, double-blind, parallel group, comparison of inhaled salmeterol xinafoate (42mcg BID) with oral zafirlukast (20mg BID) in subjects with mild to moderate asthma.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Rickard K. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol. 103:1075-1080, 1999.
Medical condition
Asthma
Product
salmeterol
Collaborators
Not applicable
Study date(s)
September 1997 to December 1997
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1997-24-12
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website